Antibody responses in invasive group B streptococcal infection in adults

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 569-572

  Wessels, Michael R ^a   Kasper, Dennis L ^b   Johnson, Kenneth D ^b   Harrison, Lee H ^b  

^a Charming Laboratory   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION;

EID: 0031848315     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517476     Document Type: Article

References (15)

1. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR 1992;41:25-32.
2. Parley MM, Harvey RC, Stull T, et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993;328:1807-11.
3. Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995:123:415-20.
4. Gotoff SP, Papierniak CK, Klegerman ME, Boyer KM. Quantitation of IgG antibody to the type-specific polysaccharide of group B streptococcus type Ib in pregnant women and infected infants. J Pediatr 1984; 105:628-30.
5. Baker CJ, Kasper DL. Group B streptococcal vaccines. Rev Infect Dis 1985;7:458-67.
6. Gray BM, Pritchard DG, Dillon Jr HC. Seroepidemiology of group B Streptococcus type III colonization at delivery. J Infect Dis 1989; 159: 1139-42.
7. Wessels MR, Kasper DL. The changing spectrum of group B streptococcal disease. N Engl J Med 1993;328:1843-4.
8. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14.
9. Ouchterlony O. Diffusion-in-gel methods for immunological analysis. Prog Allergy 1958; 5:1-78.
10. Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996; 173:142-50.
11. Baltimore RS, Kasper DL, Baker CJ, Goroff DK. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol 1977; 118:673-8.
12. Feldman RG, Ferrante A. Prevalence of anti-group B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses. J Infect Dis 1990; 162:883-7.
13. Wessels MR, Paoletti LC, Rodewald AK, et al. Stimulation of protective antibodies against type la and Ib group B streptococci by a type la polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1993; 61:4760-6.
14. Blumberg HM, Stephens DS, Modansky M, et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173: 365-73.
15. Harrison LH, Elliott JA, Dwyer DM, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine development. J Infect Dis 1998; 177:998-1002.